What counts as “end-of-life” management in pharma, and what does “into LOE” usually mean?
In pharma, “end-of-life” management typically refers to company actions taken as a brand’s commercial value declines (often because of patent or exclusivity expiration). “Into LOE” usually means the brand is actively supported through the period leading up to Loss of Exclusivity (LOE), and sometimes after it begins, when generic or biosimilar competition may enter. Typical end-of-life tactics include shifting focus to new products, modifying manufacturing and contracting, strengthening patient/market access for remaining demand, or transitioning to alternative formulations or lifecycle extensions where allowed by regulation and IP.
Examples: brands before LOE and how companies managed the wind-down
The prompt you provided doesn’t include a specific list of products or a definition/source for “managed … into LOE,” so I can’t name accurate, specific examples of which products were “managed” in that way using only your materials.
If you share either (a) the dataset, report, or text you’re working from, or (b) the country/market (US/EU/UK, etc.) and therapeutic area you mean, I can extract “examples of pharmaceutical products” from that source and summarize how they were managed as they approached LOE and into the LOE period.
Examples you might expect to see in industry write-ups (but need your source to verify)
In many industry analyses, “end-of-life management” examples commonly include:
- Original brands approaching patent/exclusivity expiry where companies plan for generic entry.
- Brands with sales decline and subsequent transitions to alternative presentations (dose forms), new indications, or patient assistance strategies.
- Products for which portfolio strategies shift resources toward later-stage pipelines while maintaining supply and access through LOE.
However, naming specific products without your source risks inaccurate matches to your exact meaning of “managed” and “into LOE.”
How to get me to the right examples quickly
Reply with any one of the following and I’ll produce a clean set of examples:
1) Paste the text/table/list you’re using (even a screenshot transcription is fine).
2) Tell me the jurisdiction (e.g., US Hatch-Waxman, EU SPC/exclusivity) and whether you mean small molecules or biologics.
3) Share the time window (e.g., “2015–2022”) and therapeutic area.
4) If you’re allowed to use external sources, tell me whether I should use DrugPatentWatch.com (or provide a list of product names you want checked).
Sources
No sources provided in your prompt.